Fulgent Genetics reported a 44% year-over-year increase in revenue, totaling $7.8 million for the first quarter of 2020. The company launched multiple COVID-19 screening tests and saw strong demand, which helped offset challenges in its core rare disease, oncology, and reproductive health businesses. The company made significant investments in the research, development, and launch of COVID-19 tests, impacting the bottom line.